These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 12559513)

  • 21. Stimulated PBMC-produced IFN-γ and TNF-α are associated with altered relapse risk in multiple sclerosis: results from a prospective cohort study.
    Simpson S; Stewart N; van der Mei I; Otahal P; Charlesworth J; Ponsonby AL; Blizzard L; Dwyer T; Pittas F; Gies P; Taylor B
    J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):200-7. PubMed ID: 24790215
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized study of antibodies to IFN-gamma and TNF-alpha in secondary progressive multiple sclerosis.
    Skurkovich S; Boiko A; Beliaeva I; Buglak A; Alekseeva T; Smirnova N; Kulakova O; Tchechonin V; Gurova O; Deomina T; Favorova OO; Skurkovic B; Gusev E
    Mult Scler; 2001 Oct; 7(5):277-84. PubMed ID: 11724442
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis.
    Hamamcioglu K; Reder AT
    Mult Scler; 2007 May; 13(4):459-70. PubMed ID: 17463069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MRI as an outcome in multiple sclerosis clinical trials.
    Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
    Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary and secondary progressive multiple sclerosis.
    Vukusic S; Confavreux C
    J Neurol Sci; 2003 Feb; 206(2):153-5. PubMed ID: 12559503
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased production of tumor necrosis factor alpha, and not of interferon gamma, preceding disease activity in patients with multiple sclerosis.
    van Oosten BW; Barkhof F; Scholten PE; von Blomberg BM; Adèr HJ; Polman CH
    Arch Neurol; 1998 Jun; 55(6):793-8. PubMed ID: 9626770
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Defective regulation of IFNgamma and IL-12 by endogenous IL-10 in progressive MS.
    Balashov KE; Comabella M; Ohashi T; Khoury SJ; Weiner HL
    Neurology; 2000 Jul; 55(2):192-8. PubMed ID: 10908889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Similar pro- and anti-inflammatory cytokine production in the different clinical forms of multiple sclerosis.
    Durán I; Martínez-Cáceres EM; Brieva L; Tintoré M; Montalban X
    Mult Scler; 2001 Jun; 7(3):151-6. PubMed ID: 11475437
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early central atrophy rate predicts 5 year clinical outcome in multiple sclerosis.
    Lukas C; Minneboo A; de Groot V; Moraal B; Knol DL; Polman CH; Barkhof F; Vrenken H
    J Neurol Neurosurg Psychiatry; 2010 Dec; 81(12):1351-6. PubMed ID: 20826873
    [TBL] [Abstract][Full Text] [Related]  

  • 30. T2 lesions and rate of progression of disability in multiple sclerosis.
    Mostert JP; Koch MW; Steen C; Heersema DJ; De Groot JC; De Keyser J
    Eur J Neurol; 2010 Dec; 17(12):1471-5. PubMed ID: 20500805
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cortical atrophy is relevant in multiple sclerosis at clinical onset.
    Calabrese M; Atzori M; Bernardi V; Morra A; Romualdi C; Rinaldi L; McAuliffe MJ; Barachino L; Perini P; Fischl B; Battistin L; Gallo P
    J Neurol; 2007 Sep; 254(9):1212-20. PubMed ID: 17361339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interferon gamma production in blood lymphocytes correlates with disability score in multiple sclerosis patients.
    Petereit HF; Richter N; Pukrop R; Bamborschke S
    Mult Scler; 2000 Feb; 6(1):19-23. PubMed ID: 10694841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cervical cord lesion load is associated with disability independently from atrophy in MS.
    Kearney H; Altmann DR; Samson RS; Yiannakas MC; Wheeler-Kingshott CA; Ciccarelli O; Miller DH
    Neurology; 2015 Jan; 84(4):367-73. PubMed ID: 25540312
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis.
    Vukusic S; Confavreux C
    J Neurol Sci; 2003 Feb; 206(2):135-7. PubMed ID: 12559500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lower levels of glutathione in the brains of secondary progressive multiple sclerosis patients measured by 1H magnetic resonance chemical shift imaging at 3 T.
    Choi IY; Lee SP; Denney DR; Lynch SG
    Mult Scler; 2011 Mar; 17(3):289-96. PubMed ID: 20921235
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigation of outer cortical magnetisation transfer ratio abnormalities in multiple sclerosis clinical subgroups.
    Samson RS; Cardoso MJ; Muhlert N; Sethi V; Wheeler-Kingshott CA; Ron M; Ourselin S; Miller DH; Chard DT
    Mult Scler; 2014 Sep; 20(10):1322-30. PubMed ID: 24552746
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized crossover study of bee sting therapy for multiple sclerosis.
    Wesselius T; Heersema DJ; Mostert JP; Heerings M; Admiraal-Behloul F; Talebian A; van Buchem MA; De Keyser J
    Neurology; 2005 Dec; 65(11):1764-8. PubMed ID: 16221950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
    Sormani MP; Rovaris M; Comi G; Filippi M
    Neurology; 2009 Nov; 73(19):1538-42. PubMed ID: 19794123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.
    Montalban X; Sastre-Garriga J; Tintoré M; Brieva L; Aymerich FX; Río J; Porcel J; Borràs C; Nos C; Rovira A
    Mult Scler; 2009 Oct; 15(10):1195-205. PubMed ID: 19797261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study.
    Thompson AJ; Kermode AG; MacManus DG; Kendall BE; Kingsley DP; Moseley IF; McDonald WI
    BMJ; 1990 Mar; 300(6725):631-4. PubMed ID: 2138923
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.